Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization-Reference-Cited by-同舟云学术

Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization

Published:2020-06 Issue: Volume:220 Page:182-190
ISSN:1931-5244
Container-title:Translational Research
language:en
Short-container-title:Translational Research

Author:

Outterson Kevin^ORCID,Rex John H.

Funder

Biomedical Advanced

Research and Development

Authority

National Institute for Allergy and Infectious Diseases

Department of Health

Boston University

Publisher

Elsevier BV

Subject

Biochemistry (medical),Public Health, Environmental and Occupational Health,General Medicine,Physiology (medical)

Reference33 articles.

1. Global Action Plan on Antimicrobial Resistance,2015

2. To the G20: incentivising antibacterial research and development;Ardal;Lancet Infect Dis,2017

3. The global preclinical antibacterial pipeline;Theuretzbacher;Nat Rev Microbiol,2019

4. Public Health Agency of Sweden. Availability of antibiotics. Access online on 6 Feb 2020 at https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/antibiotics-and-antimicrobial-resistance/availability-of-antibiotics/, 2019.

5. Aligning Payment And Prevention To Drive Antibiotic Innovation For Medicare Beneficiaries;Verma;Health Affairs Blog,2019

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action;The Lancet Microbe;2024-06

2. A New “Non-Traditional” Antibacterial Drug Fluorothiazinone—Clinical Research in Patients with Complicated Urinary Tract Infections;Antibiotics;2024-05-22

3. Addressing the Research and Development Gaps in Modern Phage Therapy;PHAGE;2024-03-01

4. Promising strategies employing nucleic acids as antimicrobial drugs;Molecular Therapy - Nucleic Acids;2024-03

5. Implications of two-component systems EnvZ/OmpR and BaeS/BaeR in in vitro temocillin resistance in Escherichia coli;Journal of Antimicrobial Chemotherapy;2024-02-02